The Relative Strength (RS) Rating for Constellium Cl A jumped into a higher percentile Tuesday, as it got a lift from 68 to 71.
Can You Really Time The Stock Market?
IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating of at least 80 as they launch their largest climbs. See if Constellium Cl A can continue to rebound and clear that threshold.
Constellium Cl A is now considered extended and out of buy range after clearing a 12.40 buy point in a first-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 86%, compared to 0% in the prior report. Revenue increased from -3% to 5%. The next quarterly results are expected on or around Jul. 23.
Constellium Cl A holds the No. 4 rank among its peers in the Steel-Specialty Alloys industry group. Carpenter Technology is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
